New Market Research Report Reveals Growth Opportunities in the Cancer Diagnostics Industry 2023-2030

 Cancer Diagnostics Industry Data Book | Forecast 2030

Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030

Grand View Research’s cancer diagnostics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.

Access the Global Cancer Diagnostics Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking,
macro-environmental analyses, and regulatory & technological framework studies

Breast Cancer Diagnostics Market Report Highlights

The global breast cancer diagnostics market size is expected to reach USD 6.8 billion by 2028, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 7.0% from 2021 to 2028.

• The imaging segment held the largest revenue share in 2020 and the blood tests segment is expected to grow at the fastest rate

 

• By product, the instrument-based products segment accounted for the largest revenue share in 2020 due to government initiatives such as mandatory screening in developed countries such as the U.S., Canada, and the U.K. for women above 45 years of age, increasing the overall testing and screening of breast cancer

 

• The platform-based products segment is expected to witness the fastest growth over the forecast period. These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women

 

• By application, the diagnostic and predictive segment dominated the market in 2020 and the prognostic segment is expected to witness the fastest CAGR over the forecast period due to increasing collaborations and efforts for advancements in diagnostics

 

• The hospitals and clinics segment dominated the market in 2020

 

• The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR

 

Order your copy of the Free Sample of “Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030”, Data Book published by Grand View Research

 

Cervical Cancer Diagnostic Market Report Highlights

 

The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is expected to reach a value of USD 12 billion by 2024, according to a new report by Grand View Research, Inc.

 

• In 2015, the Pap testing segment held majority of the market share of 49.6%. The segment’s large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.

 

• In 2015, North America was the leading regional market with a revenue share of 48.3%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country’s large market share.

 

• Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 9.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region’s high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth

 

• This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.

 

Go through the table of content of Cancer Diagnostics Industry Data Book to get a better understanding of the Coverage & Scope of the study

 

Liver Cancer Diagnostics Market Report Highlights

 

The global liver cancer diagnostics market size is expected to reach USD 14.67 billion by 2030, advancing at a CAGR of 6.67% over the forecast period from 2023 to 2030, according to a new report by Grand View Research, Inc.

 

• On basis of test type, laboratory tests held the largest share in 2022, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth

 

• Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2022. The preference for these settings In addition, the developing economies will boost the adoption of diagnostic tests in the region’s emerging countries as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment’s growth

 

• North America accounted for the highest share in 2022 due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth

 

• Asia Pacific will exhibit the fastest growth during the forecast period of 2023-2030, owing to the prevalence of diseases and the presence of a large geriatric population in the region.

 

Lung Cancer Diagnostics Market Report Highlights

 

The global lung cancer diagnostics market is expected to reach USD 3,644.6 million by 2024, according to a new report by Grand View Research Inc.

 

• The small cell lung cancer segment accounted for around 15% market share in 2015. This is an aggressive subtype of the lung malignancies, which has proven to be fatal within a short period of time if left undiagnosed.

 

• Non-small cell lung cancer was identified as the largest segment in 2015 with revenue of over USD 1,300.0 million. This is majorly due to the availability of novel lung cancer diagnostics that facilitate the detection of large tumor growths.

 

• The imaging tests segment was identified as the largest revenue generating segment in 2015 with a market share of around 50%. Major factors responsible for the large market share include the frequent use of various imaging techniques such as CT scan, X-ray, and MRI in the detection of lung malignancies coupled with the increased availability of the diagnostic tools.

 

• The molecular testing segment is expected to grow at a profitable rate of around 10% over the forecast period. The introduction of novel molecular testing techniques coupled with the increasing number of investments to support the research and development efforts for the development of biomarker-based molecular testing in lung cancer detection is expected to foster the demand of this segment over the forecast period.

 

• In 2015, North America accounted for the largest revenue share of over 30% majorly due to supportive government policies in the region coupled with the availability of technology-enabled lung cancer diagnostics

 

• Asia Pacific region is expected to reach a revenue share of over 28% by 2024. Major factors responsible for the growth include the constantly improving healthcare infrastructure, the growing awareness of the disease symptoms, and a wide base of unmet clinical needs in the developing countries in the region.

 

• Major players of this market include bioMérieux, Roche Diagnostics, Qiagen N.V., Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, Janssen, AstraZeneca plc, and Sanofi S.A.

 

• Novel product launches in the lung cancer diagnostics product portfolio is one of the major strategic initiatives adopted by the market players. For instance, Orion genomics is involved in the development of novel biomarkers for lung cancer diagnosis. Allegro Diagnostics is involved in the development and commercialization of pulmonary genomics-based lung cancer diagnostics.

 

Pancreatic Cancer Diagnostic Market Report Highlights

 

The global pancreatic cancer diagnostic market size is expected to reach USD 3.90 billion by 2030, according to a new report by Grand View Research, Inc. Furthermore, the industry is expected to expand at a CAGR of 6.53% over the forecast period.

 

• The consumables segment held the largest revenue share in 2022, owing to the rising adoption of consumables in diagnostic procedures, increased R&D investments, and growing instances of launches of technologically advanced diagnostic kits and reagents

 

• The imaging test segment accounted for the largest market revenue share in 2022 due to its ability to allow healthcare professionals to detect and diagnose pancreatic cancer at earlier stages and the high preference for imaging modules to position tumors

 

• Based on end-use, the hospital segment dominated the market in 2022, whereas the laboratories segment is projected to be the fastest-growing segment over the forecast period

 

• Asia Pacific is projected to exhibit the fastest growth over the forecast period due to the high unmet needs of the patient population and the increasing investment of key market players in the region

 

 

Ovarian Cancer Diagnostics Market Report Highlights

The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%.

• Incidence of ovarian cancer worldwide has been declining over the past decades

 

• Although ultrasound imaging is the fist-line of diagnosis, the technique cannot be used for staging the disease

 

• Computerized Tomography (CT) imaging is preferred for staging the disease

 

• CA125 remained the mainstay in blood test biomarkers in 2018

 

• HER2 and BRCA1/2 tests are expected to witness a rapid growth during the forecast period owing to the rising awareness of early diagnosis and genetic tests

 

• The ovarian cancer diagnostics market in Asia Pacific is expected to grow at a high rate during the forecast period.

 

 

Competitive Insights

 

Key players in this market are implementing various strategies including partnerships, mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in February 2023, F. Hoffmann-La Roche Ltd. announced extending its collaboration with Janssen to advance personalized healthcare by focusing on companion diagnostics.

Key Players

• GE Healthcare
• Abbott
• Hoffmann-La Roche Ltd.,
• QIAGEN
• BD
• Siemens Healthcare GmbH,
• Thermo Fisher Scientific; Inc.
• Hologic, Inc.
• Koninklijke Philips N.V. (Philips)
• IIumina, inc.

 

Check out more Industry Data Books, published by Grand View Research

 

About Grand View Research

 

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/sector-reports-list

Follow Us: LinkedIn | Twitter